Arthritis Rheumatol 2020 Sep 6
Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.
Related Questions
In a patient for whom rituximab is the best option for their disease management.
New answer by at Wright State University (April 3, 2023)
3% of patients treated with Rituxan may have delayed neutropenia. I would not re-challenge them with Rituxan and would consider giving the Neupogen to raise the patient's WBC ...